Volitionrx LTD Form 4 insider transactions

VolitionRx's Chief Commercial Officer, Gael Forterre, reported the disposition of 5,251 common shares for tax withholding related to restricted stock unit settlement.

VolitionRx's Secretary, Rodney Gerard Rootsaert, reported a disposition of shares to cover tax obligations related to restricted stock unit vesting.

VolitionRx Chief Scientific Officer Jacob Vincent Micallef reported a transaction involving the withholding of 5,310 common shares to cover tax obligations from restricted stock unit settlement.

A Form 4 filing details the withholding of 7,003 VolitionRx shares from officer Nicholas Plummer to cover tax obligations upon the settlement of 14,900 restricted stock units.

VolitionRx's Chief Commercial Officer, Gael Forterre, was awarded 149,000 restricted stock units as part of the company's 2024 Stock Incentive Plan, in lieu of cash compensation.

VolitionRx director Ethel Rubin was awarded 178,000 restricted stock units, effective February 26, 2026, in lieu of cash compensation.

VOLITIONRX LTD's President and CEO, Cameron John Reynolds, was awarded 486,000 restricted stock units in lieu of cash compensation, vesting through February 2027.

VolitionRx's Group Chief Marketing Officer, Ann-Louise Batchelor, received 142,000 restricted stock units as deferred compensation, aligning her interests with shareholders.

VolitionRx's Chief Financial Officer, Terig Hughes, was awarded 202,000 restricted stock units under the company's 2024 Stock Incentive Plan.

VolitionRx's Secretary, Rodney Gerard Rootsaert, received an award of 119,000 restricted stock units in lieu of cash compensation, vesting over time.

VolitionRx's General Counsel, Nicholas Plummer, received 187,000 restricted stock units as part of the company's 2024 Stock Incentive Plan, replacing cash compensation.

VolitionRx Ltd. Director Kim Nguyen received an award of 178,000 restricted stock units in lieu of cash compensation, vesting through February 2027.

Jasmine Kway, CEO of VolitionRx Singapore, received 173,000 restricted stock units as part of her compensation, vesting through February 2027.

VolitionRx's Chief Scientific Officer, Jacob Vincent Micallef, was awarded 149,000 restricted stock units in lieu of cash compensation, vesting through February 2027.

VolitionRx Director Guy Archibald Innes received 178,000 restricted stock units as compensation, vesting through February 2027.

VolitionRx's Chief Commercial Officer, Gael Forterre, reported a routine tax withholding of 2,010 shares related to restricted stock unit settlement.

VolitionRx's Secretary, Rodney Gerard Rootsaert, had 3,196 shares withheld by the company to cover tax obligations related to the settlement of restricted stock units.

VolitionRx General Counsel Nicholas Plummer reported a disposition of shares to cover tax obligations from restricted stock unit settlement.

VolitionRx Director Ethel Rubin acquired 12,000 shares of common stock through the vesting of restricted stock units, increasing her beneficial ownership to 74,948 shares.

VolitionRx Ltd. Director Guy Archibald Innes acquired 12,000 shares of common stock following the vesting of restricted stock units.

VolitionRx's Chief Commercial Officer, Gael Forterre, vested 38,100 restricted stock units, part of a larger award tied to performance goals and a three-year time-based schedule.

VolitionRx CEO Cameron John Reynolds reported the vesting of 74,700 restricted stock units and the cancellation of 174,300 units, with vested shares subject to a three-year time-based schedule.

VolitionRx Director Alan Colman reported the acquisition of 12,000 common shares through the vesting of restricted stock units.

VolitionRx Director Timothy I. Still reported the vesting of 90,000 restricted stock units and the cancellation of 210,000 RSUs from a 2025 award.

VolitionRx's Group Chief Marketing Officer, Ann-Louise Batchelor, acquired 33,900 common shares through the partial vesting of restricted stock units.

VolitionRx CFO Terig Hughes acquired 49,200 shares of common stock through the vesting of restricted stock units, increasing his direct beneficial ownership to 482,970 shares.

VOLITIONRX LTD Director Phillip Barnes acquired 12,000 common shares through the vesting of restricted stock units, increasing his direct beneficial ownership to 67,368 shares.

VolitionRx's CEO of Volition Veterinary, Salvatore Thomas Butera, reported the vesting of 53,400 restricted stock units and the disposition of 99,350 common shares.

VolitionRx's Secretary, Rodney Gerard Rootsaert, reported the vesting of 28,200 restricted stock units, increasing his direct beneficial ownership of common stock.

VolitionRx's Chief Scientific Officer, Jacob Vincent Micallef, reported the vesting of 35,400 restricted stock units and the cancellation of 82,600 units.